UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the successful completion of the previously announced transaction to acquire Neurona Therapeutics Inc., including lead asset rezanecel, adding to UCB’s epilepsy portfolio.
Building on UCB’s longstanding heritage in epilepsy and its ambition to deliver differentiated solutions to patients with unmet needs, this acquisition marks a strategic expansion into regenerative medicine and advanced therapies. It further demonstrates UCB’s commitment to inorganic growth and to deliver solutions that go beyond symptomatic management.
The total transaction is valued at up to US $1.15b consisting of a US $650m upfront payment plus up to US $500m in potential future milestone payments. UCB confirms its 2026 financial guidance with revenue expected to grow in a high single-digit to low double-digit percentage range at constant exchange rates (CER). 2026 underlying profitability, measured by adjusted EBITDA, is expected to grow in a high single-digit to mid-teens percentage range at CER.
Source: ucb.com
A phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that the biotech acquired in its $2.2 billion takeover of Forte Biosciences. Amsterdam-based argenx agreed to buy Forte in July to acquire FB102, an anti-CD122 antibody that hit the mark in a phase 1b vitiligo trial weeks before the deal.
Bayer announced plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, US. Building on more than seven billion dollars in US pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer’s long-term growth strategy.
Sterling Pharma Solutions has announced completion of an additional, large-scale GMP manufacturing suite at its dedicated bioconjugation facility in the UK, which will double capacity, as well as increasing the scale of manufacturing to 500L.
